Streptozotocin-induced type-1-diabetes disease onset in Sprague–Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity

Microbiology (United Kingdom)

Volumn 161, Issue 1, 2015, Pages 182-193

  Patterson, Elaine ^a,b,c   Marques, Tatiana M ^a,b,c   O’Sullivan, Orla ^a,b   Fitzgerald, Patrick ^a   Fitzgerald, Gerald F ^a,c   Cotter, Paul D ^a,b   Dinan, Timothy G ^a   Cryan, John F ^a   Stanton, Catherine ^a,b   Paul Ross, R ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

HLA; Human leukocyte antigen; Operational taxonomical unit; OTU; SCFA; Short chain fatty acid; Streptozotocin; STZ; T1D; Type 1 diabetes

Indexed keywords

GLUCOSE; LACTIC ACID; RNA 16S; STREPTOZOCIN; ANTINEOPLASTIC ANTIBIOTIC; VOLATILE FATTY ACID;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; BIFIDOBACTERIUM; CONTROLLED STUDY; DISEASE COURSE; DNA ISOLATION; FIRMICUTES; GLUCOSE BLOOD LEVEL; HIGH THROUGHPUT SEQUENCING; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; LACTOBACILLUS; MALE; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; ANIMAL; BIODIVERSITY; BIOSYNTHESIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; INTESTINE; METABOLISM; METAGENOME; MICROBIOLOGY; MICROFLORA;

BACTEROIDETES; BIFIDOBACTERIUM; FIRMICUTES; LACTOBACILLUS; RATTUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIODIVERSITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY ACIDS, VOLATILE; INTESTINES; LACTIC ACID; MALE; METAGENOME; MICROBIOTA; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84941736218     PISSN: 13500872     EISSN: 14652080     Source Type: Journal    
DOI: 10.1099/mic.0.082610-0     Document Type: Article

References (68)

1. Adolphe, A. B., Glasofer, E. D., Troetel, W. M., Ziegenfuss, J., Stambaugh, J. E., Weiss, A. J. and Manthei, R. W. (1975). Fate of streptozotocin (NSC-85998)in patients with advanced cancer. Cancer Chemother Rep 59, 547–556.
2. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25, 3389–3402.
3. Atkinson, M. A. and Chervonsky, A. (2012). Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia 55, 2868–2877.
4. Barcelo, A., Claustre, J., Moro, F., Chayvialle, J. A., Cuber, J. C. and Plaisancie´, P. (2000). Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 46, 218–224.
5. Bellavia, M., Tomasello, G., Romeo, M., Damiani, P., Lo Monte, A. I., Lozio, L., Campanella, C., Marino Gammazza, A., Rappa, F. and other authors (2013). Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microbiol Immunol 202, 393–406.
6. Boerner, B. P. and Sarvetnick, N. E. (2011). Type 1 diabetes: role of intestinal microbiome in humans and mice. Ann N Y Acad Sci 1243, 103–118.
7. Brown, C. T., Davis-Richardson, A. G., Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Casella, G., Drew, J. C., Ilonen, J. and other authors (2011). Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6, e25792.
8. Brugman, S., Klatter, F. A., Visser, J. T., Wildeboer-Veloo, A. C., Harmsen, H. J., Rozing, J. and Bos, N. A. (2006). Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetesprone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49, 2105–2108.
9. Burger-van Paassen, N., Vincent, A., Puiman, P. J., van der Sluis, M., Bouma, J., Boehm, G., van Goudoever, J. B., van Seuningen, I. and Renes, I. B. (2009). The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 420, 211–219.
10. Calcinaro, F., Dionisi, S., Marinaro, M., Candeloro, P., Bonato, V., Marzotti, S., Corneli, R. B., Ferretti, E., Gulino, A. and other authors (2005). Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48, 1565–1575.
11. Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Pena, A. G., Goodrich, J. K. and other authors (2010). QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, 335–336.
12. Cardwell, C. R., Stene, L. C., Joner, G., Cinek, O., Svensson, J., Goldacre, M. J., Parslow, R. C., Pozzilli, P., Brigis, G. and other authors (2008). Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 51, 726–735.
13. Carratu, R., Secondulfo, M., De Magistris, L., Iafusco, D., Urio, A., Carbone, M. G., Pontoni, G., Cartenı, M. and Prisco, F. (1999). Altered intestinal permeability to mannitol in diabetes mellitus type I. J Pediatr Gastroenterol Nutr 28, 264–269.
14. Chen, V. B., Davis, I. W. and Richardson, D. C. (2009). KING (Kinemage, Next Generation): a versatile interactive molecular and scientific visualization program. Protein Sci 18, 2403–2409.
15. De Goffau, M. C., Luopajarvi, K., Knip, M., Ilonen, J., Ruohtula, T., Harkonen, T., Orivuori, L., Hakala, S., Welling, G. W. and other authors (2013). Fecal microbiota composition differs between children with b-cell autoimmunity and those without. Diabetes 62, 1238–1244.
16. Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. and Knight, R. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 107, 11971– 11975.
17. Duffy, L. C. (2000). Interactions mediating bacterial translocation in the immature intestine. J Nutr 130 (Suppl), 432S–436S.
18. Ehehalt, S., Dietz, K., Willasch, A. M., Neu, A. and Baden Wurttemberg Diabetes Incidence Registry (DIARY) Group (2010). Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany: 20 years of the Baden-Wu¨rttemberg Diabetes Incidence Registry (DIARY). Diabetes Care 33, 338–340.
19. Finnie, I. A., Dwarakanath, A. D., Taylor, B. A. and Rhodes, J. M. (1995). Colonic mucin synthesis is increased by sodium butyrate. Gut 36, 93– 99.
20. Gibson, G. R., Willems, A., Reading, S. and Collins, M. D. (1996). Fermentation of non-digestible oligosaccharides by human colonic bacteria. Proc Nutr Soc 55, 899–912.
21. Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J., Knip, M. and other authors (2011). Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5, 82–91.
22. Greenblum, S., Turnbaugh, P. J. and Borenstein, E. (2012). Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 109, 594–599.
23. Haas, B. J., Gevers, D., Earl, A. M., Feldgarden, M., Ward, D. V., Giannoukos, G., Ciulla, D., Tabbaa, D., Highlander, S. K. and other authors (2011). Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 21, 494–504.
24. Hamer, H. M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F. J. and Brummer, R. J. (2008). Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104–119.
25. Huson, D. H., Auch, A. F., Qi, J. and Schuster, S. C. (2007). MEGAN analysis of metagenomic data. Genome Res 17, 377–386.
26. Karunanayake, E. H., Hearse, D. J. and Mellows, G. (1976). Streptozotocin: its excretion and metabolism in the rat. Diabetologia 12, 483–488.
27. King, C. and Sarvetnick, N. (2011). The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS ONE 6, e17049.
28. Kleessen, B. and Blaut, M. (2005). Modulation of gut mucosal biofilms. Br J Nutr 93 (Suppl. 1), S35–S40.
29. Kleessen, B., Hartmann, L. and Blaut, M. (2003). Fructans in the diet cause alterations of intestinal mucosal architecture, released mucins and mucosa-associated bifidobacteria in gnotobiotic rats. Br J Nutr 89, 597–606.
30. Klimesova, K., Kverka, M., Zakostelska, Z., Hudcovic, T., Hrncir, T., Stepankova, R., Rossmann, P., Ridl, J., Kostovcik, M. and other authors (2013). Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis 19, 1266–1277.
31. Knip, M., Virtanen, S. M., Becker, D., Dupre´, J., Krischer, J. P., AKerblom, H. K. and TRIGR Study Group (2011). Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulindependent diabetes mellitus in the Genetically at Risk (TRIGR). Am J Clin Nutr 94 (Suppl.), 1814S–1820S.
32. Kruskal, W. H. and Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47, 583–621.
33. Kuitunen, M., Saukkonen, T., Ilonen, J., Akerblom, H. K. and Savilahti, E. (2002). Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 35, 365–368.
34. Lenzen, S. (2008). The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia 51, 216–226.
35. Ley, R. E., Backhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D. and Gordon, J. I. (2005). Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102, 11070–11075.
36. Ley, R. E., Turnbaugh, P. J., Klein, S. and Gordon, J. I. (2006). Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023.
37. Lievin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D., Neeser, J. R. and Servin, A. L. (2000). Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47, 646–652.
38. Liou, A. P., Paziuk, M., Luevano, J. M., Jr, Machineni, S., Turnbaugh, P. J. and Kaplan, L. M. (2013). Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5, 178ra41.
39. Louis, P. and Flint, H. J. (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294, 1–8.
40. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P. and other authors (2006). Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55, 205–211.
41. Murphy, E. F., Cotter, P. D., Healy, S., Marques, T. M., O’Sullivan, O., Fouhy, F., Clarke, S. F., O’Toole, P. W., Quigley, E. M. and other authors (2010). Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59, 1635–1642.
42. Murri, M., Leiva, I., Gomez-Zumaquero, J. M., Tinahones, F. J., Cardona, F., Soriguer, F. and Queipo-Ortuno, M. I. (2013). Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 11, 46.
43. Noble, J. A. and Erlich, H. A. (2012). Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2, a007732.
44. Notkins, A. L. and Lernmark, A. (2001). Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108, 1247–1252.
45. O’Toole, P. W. and Claesson, M. J. (2010). Gut microbiota: changes throughout the lifespan frominfancy to elderly. Int Dairy J 20, 281–291.
46. Patterson, C. C., Dahlquist, G., Soltesz, G., Green, A. and EURODIAB ACE Study Group. Europe and Diabetes (2001). Is childhood-onset type I diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 44 (Suppl. 3), B9–B16.
47. Peng, L., He, Z., Chen, W., Holzman, I. R. and Lin, J. (2007). Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61, 37–41.
48. Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. and Lin, J. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139, 1619–1625.
49. Price, M. N., Dehal, P. S. and Arkin, A. P. (2010). FastTree 2– approximately maximum-likelihood trees for large alignments. PLoS ONE 5, e9490.
50. Pruesse, E., Quast, C., Knittel, K., Fuchs, B. M., Ludwig, W., Peplies, J. and Glockner, F. O. (2007). SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res 35, 7188–7196.
51. Pryde, S. E., Duncan, S. H., Hold, G. L., Stewart, C. S. and Flint, H. J. (2002). The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217, 133–139.
52. Rea, M. C., Dobson, A., O’Sullivan, O., Crispie, F., Fouhy, F., Cotter, P. D., Shanahan, F., Kiely, B., Hill, C. and Ross, R. P. (2011). Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 108 (Suppl. 1), 4639–4644.
53. Roesch, L. F., Lorca, G. L., Casella, G., Giongo, A., Naranjo, A., Pionzio, A. M., Li, N., Mai, V., Wasserfall, C. H. and other authors (2009). Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J 3, 536–548.
54. Romond, M. B., Colavizza, M., Mullie, C., Kalach, N., Kremp, O., Mielcarek, C. and Izard, D. (2008). Does the intestinal bifidobacterial colonisation affect bacterial translocation? Anaerobe 14, 43–48.
55. Sapone, A., De Magistris, L., Pietzak, M., Clemente, M. G., Tripathi, A., Cucca, F., Lampis, R., Kryszak, D., Cartenı`, M. and other authors (2006). Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55, 1443–1449.
56. Sartor, R. B. (2008). Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577–594.
57. Sartor, R. B. and Mazmanian, S. K. (2012). Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 1, 15–21.
58. Schein, P., Kahn, R., Gorden, P., Wells, S. and Devita, V. T. (1973). Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. Arch Intern Med 132, 555–561.
59. Shimotoyodome, A., Meguro, S., Hase, T., Tokimitsu, I. and Sakata, T. (2000). Short chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon. Comp Biochem Physiol A Mol Integr Physiol 125, 525–531.
60. Stecher, B. and Hardt, W. D. (2008). The role of microbiota in infectious disease. Trends Microbiol 16, 107–114.
61. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R. and Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031.
62. Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A. and other authors (2009). A core gut microbiome in obese and lean twins. Nature 457, 480–484.
63. Urich, T., Lanzen, A., Qi, J., Huson, D. H., Schleper, C. and Schuster, S. C. (2008). Simultaneous assessment of soil microbial community structure and function through analysis of the meta-transcriptome. PLoS ONE 3, e2527.
64. Vaarala, O., Atkinson, M. A. and Neu, J. (2008). The ‘‘perfect storm’’ for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57, 2555–2562.
65. Vavra, J. J., Deboer, C., Dietz, A., Hanka, L. J. and Sokolski, W. T. (1959- 1960). Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 7, 230–235.
66. Wall, R., Marques, T. M., O’Sullivan, O., Ross, R. P., Shanahan, F., Quigley, E. M., Dinan, T. G., Kiely, B., Fitzgerald, G. F. and other authors (2012). Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr 95, 1278–1287.
67. Wang, Z. T., Yao, Y. M., Xiao, G. X. and Sheng, Z. Y. (2004). Risk factors of development of gut-derived bacterial translocation in thermally injured rats. World J Gastroenterol 10, 1619–1624.
68. Wu, K. K. and Huan, Y. (2008). Streptozotocin-induced diabetic models in mice and rats. In Current Protocols in Pharmacology 5.47.1–5.47.14. Edited by S. J. Enna, M. Williams, T. Kenakin, P. McGonigle and B. Ruggeri. New York: Wiley.